Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.760
-0.040 (-2.22%)
At close: Nov 4, 2024, 4:00 PM
1.860
+0.100 (5.68%)
After-hours: Nov 4, 2024, 4:38 PM EST
Cellectis Employees
As of December 31, 2023, Cellectis had 221 total employees, including 216 full-time and 5 part-time employees. The number of employees decreased by 16 or -6.75% compared to the previous year.
Employees
221
Change (1Y)
-16
Growth (1Y)
-6.75%
Revenue / Employee
$163,086
Profits / Employee
-$382,258
Market Cap
188.09M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
TruBridge | 3,219 |
Accuray | 987 |
LifeMD | 211 |
Electromed | 174 |
NeuroPace | 171 |
Tenaya Therapeutics | 140 |
Cabaletta Bio | 103 |
Atai Life Sciences | 83 |
CLLS News
- 14 hours ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 5 days ago - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 14 days ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 2 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire
- 2 months ago - Cellectis: Cheap With Promising But Speculative Cancer Therapies - Seeking Alpha
- 2 months ago - Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors - GlobeNewsWire
- 3 months ago - Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Cellectis Provides Financial Results for the Second Quarter 2024 - GlobeNewsWire